A new pill is designed to slow the progression of Alzheimer’s and is simpler than previous therapies. The approval process in Europe has been ongoing for almost a year. However, this important research has significant flaws, experts say.
Will Blarcamesine be approved?: Experts doubt new Alzheimer’s tablets
